Relapse prevention in alcoholics with an anticraving drug treatment : first results of the Berlin Study

摘要: Lisuride--a compound with mainly dopamine d2-agonistic, but also dl-antagonistic and serotonergic properties was choosen in 1.0 mg daily dose as an anticraving drug for keeping alcoholics abstinent who had been included a randomized double-blind placebo-controlled trial 6 months. Preliminary results indicate that the first 55 recruited patients overall abstinence-rate dropped from 85% after 3 months to 47% Predictors of relapse were early onset alcohol-related problems, high number preceding detoxification rehabilitation treatments, intermittant drinking habits, less feeling guilt low harm avoidance TPQ by Cloninger. More details will be given completing study when code is lifted.